Inadequate Stroke Risk Factor Screening [transcript][audio]

Guest: Dr. Daniel Singer, MD  

Presenter: Neal Howard

Guest Bio: Daniel E. Singer is a Professor of Medicine at Harvard Medical School, Professor in the Department of Epidemiology at the Harvard School of Public Health, and Associate Chief for Research in the Division of General Internal Medicine at Massachusetts General Hospital. He is widely known for his research in the prevention of stroke in atrial fibrillation (AF). With Dr. Alan Go, Dr. Singer led the ATRIA cohort studies assessing anticoagulation for AF in real-world care. Dr. Singer was Chair for the chapter on AF in the 2004 and 2008 American College of Chest Physicians Consensus Conference on Antithrombotic and Thrombolytic Therapy and lead author of these guidelines. He continued as a co-author on the 2012 version of these guidelines. He is a member of the Executive Committee of the ROCKET AF trial that demonstrated the “non-inferiority” of the novel anticoagulant, rivaroxaban, versus warfarin as stroke preventive therapy in AF. Dr. Singer was the recipient of the 2008 C. Miller Fisher Award from the New England chapter of the American Stroke Association/American Heart Association for his contributions to stroke research.

Segment overview: Dr. Daniel Singer of Harvard discusses a recent global report issued by the Economist Intelligence Unit (EIU) that finds the majority of people at high risk of stroke aren’t being screened for common risk factors and the need for more effective screening.